This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
LogicBio Therapeutics 過去の業績
過去 基準チェック /06
主要情報
-18.2%
収益成長率
46.0%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 77.0% |
| 株主資本利益率 | -168.7% |
| ネット・マージン | -246.7% |
| 前回の決算情報 | 30 Sep 2022 |
最近の業績更新
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09収支内訳
収支内訳
LogicBio Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 22 | 11 | -27 | 14 | -8 |
| 30 Jun 22 | 10 | -31 | 15 | 0 |
| 31 Mar 22 | 8 | -36 | 16 | -1 |
| 31 Dec 21 | 5 | -40 | 16 | 0 |
| 30 Sep 21 | 4 | -38 | 15 | 8 |
| 30 Jun 21 | 3 | -36 | 14 | 1 |
| 31 Mar 21 | 3 | -33 | 13 | -1 |
| 31 Dec 20 | 3 | -33 | 12 | 0 |
| 30 Sep 20 | 3 | -37 | 12 | 8 |
| 30 Jun 20 | 2 | -40 | 11 | 17 |
| 31 Mar 20 | 1 | -42 | 11 | 32 |
| 31 Dec 19 | 0 | -40 | 10 | 31 |
| 30 Sep 19 | 0 | -32 | 10 | 27 |
| 30 Jun 19 | 0 | -29 | 10 | 21 |
| 31 Mar 19 | 0 | -23 | 9 | 15 |
| 31 Dec 18 | 0 | -18 | 7 | 11 |
| 30 Sep 18 | 0 | -18 | 5 | 8 |
| 30 Jun 18 | 0 | -11 | 4 | 6 |
| 31 Mar 18 | 0 | -9 | 3 | 5 |
| 31 Dec 17 | 0 | -8 | 2 | 4 |
質の高い収益: LOGC is currently unprofitable.
利益率の向上: LOGC is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: LOGC is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.
成長の加速: Unable to compare LOGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: LOGC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (60.8%).
株主資本利益率
高いROE: LOGC has a negative Return on Equity (-168.65%), as it is currently unprofitable.